Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Cyclophosphamide + Fludarabine + iC9/CAR.19/IL15-Transduced CB-NK|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 14||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Fludarabine||Fludara||FAMP|Fludarabine phosphate||Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary)|
|iC9/CAR.19/IL15-Transduced CB-NK||iC9/CAR.19/IL15-Transduced CB-NK cells are cord blood-derived natural killer cells that have modified to express a chimeric antigen receptor directed to CD19, as well as IL-15 and inducible caspase-9, which may result in increased death of CD19-expressing tumor cells (PMID: 28725044).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03056339||Phase Ib/II||Cyclophosphamide + Fludarabine + iC9/CAR.19/IL15-Transduced CB-NK||Umbilical & Cord Blood (CB)- Derived CAR-Engineered NK Cells for B Lymphoid Malignancies||Recruiting|